Pandemic H1N1 (2009) laboratory response Singapore.

Slides:



Advertisements
Similar presentations
Surveillance in a Pandemic: Situational Awareness
Advertisements

H3N2 variant influenza A Maine, 2011 Sara Robinson, MPH Epidemiologist Maine Center for Disease Control and Prevention.
CUPS Health and Education Centre Response to H1N1.
Influenza Surveillance In Saskatchewan Ken Brandt Manager, Virology Section Provincial Laboratory Regina, Saskatchewan.
Public health assessment Avian flu A(H5N1) situation Feb 9, 2004.
INFLUENZA A (H1N1) SWINE FLU : EVOLUTION OF THE PROBLEM BY DR ESSAM EL-GAMAL Professor of Chest Diseases Mansoura Faculty of Medicine Tuesday May, 5, 2009.
Judith A. Monroe, M.D. State Health Commissioner 28 April
U.S. Surveillance Update Anthony Fiore, MD, MPH CAPT, USPHS Influenza Division National Center for Immunizations and Respiratory Disease Centers for Disease.
George A. Ralls M.D. Dave Freeman Health Services Department September 1st, 2009 INFLUENZA UPDATE.
Preparing for the next flu pandemic MINISTRY OF HEALTH SINGAPORE 20 Jan 2006.
National Influenza Sentinel Surveillance Viet Nam: US CDC Collaboration and WHO Global Surveillance Network Partnership Nguyen Thanh Chung, MD,
Ethics Conference on Asian Flu Pandemic Ethical considerations among Response to H1N1 Pandemic in China China CDC, CFETP Huilai Ma, Guang Zeng.
Infectious Disease Epidemiology Section Office of Public Health Louisiana Department of Health and Hospitals
Tennessee Department of Health Pandemic Influenza Planning David Kirschke, MD Medical Epidemiologist Northeast Tennessee Regional Health Office.
Pandemic Influenza. Guidance for Pandemic Influenza: Infection Control in Hospitals and Primary Care Settings UK Pandemic Influenza Contingency Plan Operational.
TANEY COUNTY HEALTH DEPARTMENT AUGUST 2009 Situation Update: H1N1 Influenza A.
Response to pandemic (H1N1) Country experience - Japan Tomimasa Sunagawa Infectious Disease Surveillance Center National Institute.
Swine Flu Tool Kit Responding to the threat. Principles of Swine Flu Toolkit 1 Rapid Identification of Acute Respiratory Disease Identify Risk Factors.
Surveillance Activities during Pandemic Phases Anne-Luise Winter APHEO-COMOH Workshop Toronto February 1, 2007.
1 INFLUENZA (AND OTHER RESPIRATORY VIRUS) SURVEILLANCE IN WISCONSIN Thomas Haupt M.S. Wisconsin Influenza Surveillance Coordinator.
Traveling Fever The following slides represent a realistic public health crisis event and you are charged with developing first messages for the public.
Update of Antiviral Resistance in Seasonal and Pandemic Influenza Viruses 3 rd NIC Meeting, Beijing, China August th 2009 Aeron Hurt WHO Collaborating.
Influenza A H1N1: A Pandemic in Real Time – What’s Next? Danny Chen, MD FRCPC MSc Infectious Disease Specialist Grand Rounds, York Central Hospital September.
Lessons from the European Experience with A(H1N1) 2009 Angus Nicoll CBE European Centre for Disease Prevention and Control 3 rd meeting of the National.
Centers for Disease Control and Prevention Program title: Developing sustainable surveillance and response for seasonal and avian influenza. Goal: To establish.
H1N1 Influenza in Boston: Past, Present, and Future Media Briefing Boston Public Health Commission August 17, 2009.
Outbreak of influenza A (H3N2) in a residence for mentally disabled persons in Ljubljana, Slovenia, 2013 Epidemiology and Public Health Valencia, Spain.
Dr. Zhen XU Branch of Respiratory Disease Prevention and Control Division for Disease Control and Emergency Response Chinese Center for Disease Control.
Influenza and the Nursing Home Population Julie L. Freshwater, PhD MPH Influenza Surveillance Coordinator 1.
Papua New Guinea Update 3 rd NIC Meeting 18 – 20 Beijing, China Berry Ropa National CSR Officer Department of Health Papua New Guinea.
Sheila Negrini Parmezan São Paulo, Introduction The neuraminidase inhibitors (NAIs), oseltamivir and zanamivir, are currently the antiviral drugs.
Pandemic Response and current activities in Lao PDR NIC Meeting, Beijing, Aug 2009 Dr Phengta Vongphrachanh Director National centre for Laboratory.
Severe Acute Respiratory Syndrome (SARS) and Preparedness for Biological Emergencies 27 April 2004 Jeffrey S. Duchin, M.D. Chief, Communicable Disease.
Laboratory Integration in Influenza Surveillance Dr Geethani Wickramasinghe NIC- Sri Lanka.
Update: “New Flu” Activity and Community Mitigation Diane Woolard, PhD, MPH Director, Division of Surveillance and Investigation Virginia Department of.
CONNECTICUT PANDEMIC PLANNING Meg Hooper, MPA Connecticut Department of Public Health 9 Oct 2008.
US Situation Update and CDC International Response H1N1 Pandemic US Situation Update and CDC International Response Peter Nsubuga, MD, MPH On behalf of.
The Current Season: A Review of the Influenza Season Nancy J. Cox, Ph.D. Chief, Influenza Branch National Center for Infectious Diseases Centers.
Avian Influenza H5N1 Prepared by: Samia ALhabardi.
Communicable Disease Surveillance and Response, WHO Avian Influenza Credit: WHO Viet Nam.
Background: A 2007 survey of Midwestern LTCF suggested that less than 25% had a written pandemic influenza response plan. Upon request from a rural nursing.
1 |1 | Situation Update Influenza A (H1N1), 26 May 09.
Australia’s response and activities Rhonda Owen August 2009 PANDEMIC (H1N1) 2009.
THE DEVELOPMENT OF INFLUENZA SURVEILLANCE NETWORK IN THE PHILIPPINES (June 2005 – March 2008)‏ Remigio M. Olveda 1, Enrique A. Tayag 2, Analisa N. Bautista.
It’s Just Not the Flu Anymore Rick Hong, MD Associate Chairman CCHS EMC Medical Director, PHPS.
1 Influenza activity in the Southern Hemisphere Ian Barr WHO CC for Reference & Research on Influenza Melbourne The Melbourne WHO.
What Is H1N1 (Swine Flu) Pandemic Influenza? Colorized image of H1N1 from a transmission electron micrograph. Source: CDC.
Current situation and country response to Influenza A/H1N1 in Cambodia Ly Sovann, MD, DTMH, MCTM Deputy Director of CDC Department Ministry of Health,
Seoul Metropolitan Government Health & Welfare Headquarters Health Policy Division Kui-Nam Kim.
U.S. Influenza Surveillance Ann Moen Influenza Branch NCID/CDC.
WORKFLOW FOR PREGNANT WOMEN WITH SUSPECT, CONFIRMED H1N1 KKH DR CAROL TAN SENIOR CONSULTANT GERIATRICIAN MBBS, MRCP FAMS.
Screening & Investigation of Suspect Avian Influenza (H5N1) By Akrum Hamdy.
CVD Testing the H1N1 Pandemic Flu Vaccines Mini-Med School Karen Kotloff, MD University of Maryland School of Medicine Center for Vaccine Development September.
Challenges in Delivering Pandemic Vaccine from a City Health Department Perspective 43nd National Immunization Conference Fernando A. Guerra, M.D., M.P.H.
Jan 2016 Solar Lunar Data.
Avian Influenza A (H5N1) “Bird Flu”
Flu Update and Overview of Flu Surveillance in RI
Infectious Diseases Surveillance in the Military
U.S. Influenza Sentinel Provider Surveillance Network
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Presentation transcript:

Pandemic H1N1 (2009) laboratory response Singapore

Containment phase –All patients with travel history to affected countries go to one hospital (TTSH) –Later more hospitals opened up –Severe symptoms or high-risk groups: admit to hospital –Others wait at Emergency Department for laboratory test results: 6-8 hours

Transition and mitigation phase –Test only patients in high-risk groups, or those sick enough to be admitted to hospital –Influenza-like illness (ILI): stay home, MC x 7 days –ILI in vulnerable groups: empiric treatment with antiviral

Laboratory testing methods PCR for influenza A –H1N1 (2009) + H3 + H1 (seasonal) –US CDC protocol (modified for primers, machines, reagents) –Self-designed real-time and end-point PCR –Roche kit Virus isolation (MDCK) for positive PCR cases

Quality assurance of H1N1 PCR Test with virus samples –Seasonal and H1N1(2009) –Other respiratory viruses –Samples known to be positive for seasonal flu Control strain from Melbourne WHO CC External quality assurance (9 labs) –Known positive samples / RNA sent to participating labs First cases – M gene sequencing New testing labs – first 20 cases require re- testing by NPHL

Sample collection Nasopharyngeal swabs –Preferred flocked swabs in universal transport medium (UTM) Alternatives –Combined throat + nose swab –Throat swab only Diagnostic testing: 2 swabs taken within 10 minutes –Concordance almost 100%, so reduced to one swab

Testing laboratories NPHL (National Public Health Laboratory) –Obtain test protocol –Recommend and distribute primers/ probes –Obtain control strains; make RNA –Perform sequencing and virus isolation –Re-test problem cases 6 hospital labs with PCR capability –TTSH, SGH, KKH, NUH, AH, CGH

Increasing lab capacity Bought more –Robotic extractors (Qiagen, EasyMag, Qiacube, liquid handler) –Thermocyclers Hired temporary and permanent staff Use other labs: National Environment Agency, Defence Science Organization Improve workflow

Increasing lab capacity Working hours –Extended 8 am to 12 midnight + weekends –One hospital team: 24 hour service Before pandemic –<50 influenza PCR samples/ day At the peak –>1 000 samples/day

Testing objectives Diagnostic testing: 6-8 h turnaround time Test before discharge Surveillance testing Coverage for major international meetings Coverage for mass sports events –Asian Youth Games + other non-recommended situations!

Surveillance testing Before pandemic: weekly data, samples/week Pandemic –*daily* monitoring –Achieve statistical confidence to detect 1% change = 160 samples/ day

Surveillance testing Based on ILI symptoms Sentinel sites –Polyclinics (government clinics) –Private GPs –Emergency departments

Surveillance testing Support decision-making Examples –0 to 1% : ? Signal of community spread – transit into mitigation * –>15% : justifies empiric use of antivirals in susceptible groups –Future: return to 10-15% - tailing of pandemic? Monitor other parameters as well e.g. total ARI (acute respiratory illness) attendance *Estimated ARIs/ day, est ILIs/ day, therefore 1% = 40 cases 5% = 200 cases; x6 for private GPs

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Daily proportion (%) of influenza A/H1N1/2009 among all samples based on influenza surveillance of polyclinics, GP clinics, and hospitals

Note: N refers to daily no. tested.

Daily proportion (%) of influenza A/H1N1/2009 among flu A positive samples based on influenza surveillance of polyclinics, GP clinics, and hospitals Note: n refers to daily no. tested positive for Flu A.

Combined Daily Influenza Surveillance and Flu A Typing Results Note: N refers to daily no. of samples tested and n refers to daily no. tested positive for Flu A.

Daily Influenza Surveillance and Flu A Typing Results Note: N refers to daily no. of samples tested and n refers to daily no. tested positive for Flu A.

Daily Influenza Surveillance and Flu A Typing Results Note: N refers to daily no. of samples tested and n refers to daily no. tested positive for Flu A.

Continued importance of H3N2 In May 2009, we were in the middle of an H3N2 epidemic Vaccine failures in longstay residents caused influenza clusters

Position Vaccine strain and 2008 isolates ELNKNIR 2009 isolatesKIKN/RKMQ % (Jan to Feb)(n=9)22Kindergarten sample only %(Mar to May)(n=16) Isolates000R was seen in Nov and Dec 000 Emergence of new H3N2 in 2009 associated with vaccine failure

Input your sequence (a.a or n.a) Free web tool from Bioinformatics Institute, A*Star, Singapore

Automatic select reference sequence Generate report of mutations vs reference sequences

View 3D structure with a lot of features Oseltamivir-resistant H1N1 (2009) with H275Y

Mutations in seasonal H3N2 isolates Blue : residues within 3A of antibody in complex structure 2VIT Cyan: residues within 3A of antibody in complex structure 1KEN Green: residues within 3A of antibody in complex structure 1EO8 Yellow residues: mutations in your patient/sample